Skip to content
Medical Health Aged Care

Kao Corporation: Regarding Shareholder Statement

Kao Corporation 2 mins read
  • Media:
TOKYO--BUSINESS WIRE--

Oasis Management Company Ltd. (hereinafter referred to as “Oasis Management”), an investment management firm and a shareholder of our company, released a statement regarding Director candidates to be proposed at our 119th Ordinary General Meeting of Shareholders.

Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges.

Kao is constantly evolving its selection process to ensure an optimal composition of the Board of Directors. This year, the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members spent more than six months discussing the matter before reaching a final decision, and the decision was made before Oasis Management proposed any director candidates.

The timing of the announcement of Director and Auditor candidates was set for December 2nd, the standard date for announcing Executive Officers, to clearly indicate that David Muenz, a Director also serving as an Executive Officer, is retiring from his Executive Officer role at the end of December while continuing as a Director until the General Meeting of Shareholders in March.

Our selection process has been thoroughly explained to Oasis Management. In addition, regarding the director candidates for which we received specific names from the company at the end of November, we are proceeding with the appropriate screening in accordance with the selection process of the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members, and have directly communicated this to Oasis Management. Nevertheless, the recent claims include inaccurate statements, such as “the Directors refused to be transparent”, “Kao’s offer to interview the candidates…is clearly disingenuous”, and that Kao has taken “an approach to director nominations that falls well short of the due process expected from public companies.”

Oasis Management claims that "Kao has announced that it has significantly delegated authority to management, and thus abandoned its oversight function," in reaction to a statement in the announcement that Kao released on December 2nd. This reflects our existing approach of delegating authority within the scope permitted under Japan’s Companies Act while further strengthening supervisory functions to enable swift and decisive decision-making. It does not involve changes to our governance structure.

Kao will continue to pursue highly transparent and effective governance, while at the same time implementing the K27 strategy and making every effort to increase its corporate value.


Contact details:

Media inquiries should be directed to:
Public Relations
Kao Corporation
corporate_pr@kao.com

Media

Images

Kao_Logo_green.jpg

Download media

More from this category

  • Medical Health Aged Care
  • 29/01/2025
  • 02:26
King Faisal Specialist Hospital & Research Centre

KFSHRC’s DCEO Highlights Medical Tourism Growth at Arab Health 2025

Advanced Tech and Global Collaborations Attract Patients from 17 CountriesRIYADH, Saudi Arabia, Jan. 28, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) Deputy Chief Executive Officer, Dr. Björn Zoëga, represented KFSHRC at the region’s premier healthcare event, Arab Health 2025, held recently in Dubai. Dr. Zoëga participated in a panel discussion titled “Investing in KSA’s Healthcare Future”.The panel discussion emphasized KFSHRC’s critical contributions to advancing Saudi Arabia’s healthcare sector and its ambition to become a global healthcare hub. Dr. Zoëga highlighted how KFSHRC’s adoption of advanced technologies, including AI-powered diagnostics, robotic-assisted surgeries, and telemedicine services, supports…

  • Medical Health Aged Care
  • 29/01/2025
  • 00:11
Zenas BioPharma

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management’s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.About Zenas BioPharma, Inc.Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader…

  • Medical Health Aged Care, Research Development
  • 28/01/2025
  • 21:29
UNSW Sydney Centre for Healthy Brain Ageing (CHeBA)

Success in online lifestyle trial to improve cognition in older adults

Cognitive decline can lead to dementia, making improving cognition as you age key to prevention. A clinical trial has shown an internet-delivered lifestyle intervention has resulted in significantly better cognition in older adults. The team, led by Professor Henry Brodaty AO, Co-Director of UNSW’s Centre for Healthy Brain Ageing (CHeBA), calculated a global cognition score from online tests that measured memory, reasoning and speed of information processing, and published their findings in Nature Medicine today. The landmark trial, known as Maintain Your Brain, is the largest internet-based trial ever conducted to attempt to prevent cognitive decline and dementia. The researchers…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.